Discovery on How Glioblastoma Cells Disrupt Brain's Barrier Leads to Potential Therapies
the Cancer Therapy Advisor take:
Glioblastoma is an aggressive, devastating type of brain tumor that spreads rapidly. According to a mice study published in Nature Communications, researchers found that during the early stages of glioblastoma progression that glioblastoma cells took over cerebral blood vessels, which damaged the blood-brain barrier (BBB).
The BBB protects the brain from harmful materials threatening to leak inside of it, and the BBB also regulates the transportation of important molecules between the blood and the brain. Parts of the BBB are tight junctions that make seals between blood vessels’ endothelial cells. A specialized brain cell, known as an astrocyte, has extensive projections called endfeet and covers blood vessels. The endfeet regulate the brain’s blood flow by releasing chemicals that make blood vessels contract or expand.
Harald Sontheimer, PhD, and his colleagues studied glioblastoma cells, astrocytes, and cerebral blood vessels and how they interact with each other. The researchers found that a majority of the glioblastoma cells outside of the tumor resided between the endfeet and the blood vessel’s outer surface. The glioblastoma cells migrated along blood vessels, took the blood’s nutrients, and hijacked the astrocytes’ control over blood flow, which caused the BBB’s breakdown.
These findings could lead to new treatments using anti-invasive agents for glioblastoma.
Discovery on How Glioblastoma Cells Disrupt Brain’s Barrier Leads to Potential Therapies
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM